Clinically, intravenous anti-CD20 mAb therapy typically induces a rapid decrease in circulating CLL cells (within hours), followed by a long period (days) of stable to increased levels of circulating cells. Similarly, our live cell time-lapse video assay shows initial rapid ADCP over the first ...
( 2008 ) Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment . Arthritis and Rheumatism , 58 , 1566 – 1575 .Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of ...
2, 3, 4, 5 These patients can have severe and progressive disease despite prolonged antimicrobial therapy, which can result in drug toxicity and therapeutic failure. Rituximab is a chimeric mAb directed against human CD20 on mature B cells and plasmablasts that causes rapid and sustained depletion...
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.This is a modal window. The Playback API request failed for an unknown reason...
Anti-CD20 therapy of ocular disordersdoi:CN1845755 A本申请描述了利用结合CD-20的拮抗剂诸如抗体的眼部疾病的治疗。 The present application describes the use of binding CD-20 antagonist treatment of eye diseases such as antibodies.保罗·G·布鲁尼塔...
Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggregating FcγRIIIA/CD16, contributing significantly to the therapeutic effect of CD20 monoclonal antibodies (mAb). In this study, we show that CD16 ligation on primary human NK cells by the anti-CD20...
Agents which have efficacy in the treatment of autoimmune disorders have been utilized as therapy for established chronic GVHD and are associated with ... V Ratanatharathorn,L Ayash,HM Lazarus,... - 《Bone Marrow Transplantation》 被引量: 1159发表: 2001年 Anti-CD20 Chimeric Monoclonal Antibody ...
Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis,complement activation and antibody dependent cellular cytotoxicity. Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies....
CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy Despite cutaneous B-cell lymphoma often having a relatively indolent course and low mortality, it is often resistant to conventional therapy and frequently... William,Trent,Massengale,... - 《Journal of ...
Abstract A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with ha...